Last reviewed · How we verify
Huazhi Rougan granule
Huazhi Rougan granule is a traditional Chinese medicine formulation designed to support liver function and promote hepatic health through its herbal constituents.
Huazhi Rougan granule is a traditional Chinese medicine formulation designed to support liver function and promote hepatic health through its herbal constituents. Used for Liver support and hepatic function (traditional indication).
At a glance
| Generic name | Huazhi Rougan granule |
|---|---|
| Sponsor | Shandong New Time Pharmaceutical Co., LTD |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Traditional Chinese Medicine |
| Phase | FDA-approved |
Mechanism of action
This is a Chinese herbal medicine granule preparation intended to address liver-related conditions and support hepatic metabolism. The specific active compounds and their molecular targets are not well-characterized in Western pharmaceutical literature, as this product operates within the traditional Chinese medicine framework rather than conventional pharmacology.
Approved indications
- Liver support and hepatic function (traditional indication)
Common side effects
Key clinical trials
- Huazhi Rougan Granule as an Add-On Therapy for H. Pylori Infection With Metabolic-associated Steatohepatitis (NA)
- A Phase IV Study of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver (PHASE4)
- A Phase IV Study of Huazhi Rougan Granule (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Huazhi Rougan granule CI brief — competitive landscape report
- Huazhi Rougan granule updates RSS · CI watch RSS
- Shandong New Time Pharmaceutical Co., LTD portfolio CI